{ "resourceType" : "ValueSet", "id" : "R2-v3-substanceAdminSubstitution-for-R5", "text" : { "status" : "generated", "div" : "

Generated Narrative: ValueSet R2-v3-substanceAdminSubstitution-for-R5

This value set expansion contains 10 concepts.

SystemVersionCodeDisplayDefinition
http://hl7.org/fhir/v3/substanceAdminSubstitution1.0.2\u00a0\u00a0BCbrand compositionDescription: Substitution occurred or is permitted between equivalent Brands but not Generics Examples: Zestril for Prinivil Coumadin for Jantoven
http://hl7.org/fhir/v3/substanceAdminSubstitution1.0.2\u00a0\u00a0EequivalentDescription: Substitution occurred or is permitted with another bioequivalent and therapeutically equivalent product.
http://hl7.org/fhir/v3/substanceAdminSubstitution1.0.2\u00a0\u00a0ECequivalent compositionDescription: Substitution occurred or is permitted with another product that is a: pharmaceutical alternative containing the same active ingredient but is formulated with different salt, ester pharmaceutical equivalent that has the same active ingredient, strength, dosage form and route of administration Examples: Pharmaceutical alternative: Erythromycin Ethylsuccinate for Erythromycin Stearate Pharmaceutical equivalent: Lisonpril for Zestril
http://hl7.org/fhir/v3/substanceAdminSubstitution1.0.2\u00a0\u00a0FformularyDescription: This substitution was performed or is permitted based on formulary guidelines.
http://hl7.org/fhir/v3/substanceAdminSubstitution1.0.2\u00a0\u00a0Ggeneric compositionDescription: Substitution occurred or is permitted between equivalent Generics but not Brands Examples: Lisnopril (Lupin Corp) for Lisnopril (Wockhardt Corp)
http://hl7.org/fhir/v3/substanceAdminSubstitution1.0.2\u00a0\u00a0NnoneNo substitution occurred or is permitted.
http://hl7.org/fhir/v3/substanceAdminSubstitution1.0.2\u00a0\u00a0TBtherapeutic brandDescription: Substitution occurred or is permitted between therapeutically equivalent Brands but not Generics > Examples: Zantac for Tagamet
http://hl7.org/fhir/v3/substanceAdminSubstitution1.0.2\u00a0\u00a0TEtherapeutic alternativeDescription: Substitution occurred or is permitted with another product having the same therapeutic objective and safety profile. Examples: ranitidine for Tagamet
http://hl7.org/fhir/v3/substanceAdminSubstitution1.0.2\u00a0\u00a0TGtherapeutic genericDescription: Substitution occurred or is permitted between therapeutically equivalent Generics but not Brands > Examples: Ranitidine for cimetidine
http://hl7.org/fhir/v3/substanceAdminSubstitution1.0.2\u00a0\u00a0_ActSubstanceAdminSubstitutionCodeActSubstanceAdminSubstitutionCodeDescription: Substitution occurred or is permitted with another product that may potentially have different ingredients, but having the same biological and therapeutic effects.
" }, "extension" : [{ "url" : "http://hl7.org/fhir/StructureDefinition/structuredefinition-wg", "valueCode" : "fhir" }, { "extension" : [{ "url" : "packageId", "valueId" : "hl7.fhir.uv.xver-r2.r5" }, { "url" : "version", "valueString" : "0.1.0" }, { "url" : "uri", "valueUri" : "http://hl7.org/fhir/uv/xver/ImplementationGuide/hl7.fhir.uv.xver-r2.r5" }], "url" : "http://hl7.org/fhir/StructureDefinition/package-source" }, { "url" : "http://hl7.org/fhir/StructureDefinition/structuredefinition-fmm", "valueInteger" : 0, "_valueInteger" : { "extension" : [{ "url" : "http://hl7.org/fhir/StructureDefinition/structuredefinition-conformance-derivedFrom", "valueCanonical" : "http://hl7.org/fhir/uv/xver/ImplementationGuide/hl7.fhir.uv.xver-r2.r5" }] } }, { "url" : "http://hl7.org/fhir/StructureDefinition/structuredefinition-standards-status", "valueCode" : "trial-use", "_valueCode" : { "extension" : [{ "url" : "http://hl7.org/fhir/StructureDefinition/structuredefinition-conformance-derivedFrom", "valueCanonical" : "http://hl7.org/fhir/uv/xver/ImplementationGuide/hl7.fhir.uv.xver-r2.r5" }] } }], "url" : "http://hl7.org/fhir/uv/xver/ValueSet/R2-v3-substanceAdminSubstitution-for-R5", "version" : "0.1.0", "name" : "R2V3SubstanceAdminSubstitutionForR5", "title" : "Cross-version ValueSet DSTU2.v3 Code System substanceAdminSubstitution for use in FHIR R5", "status" : "active", "experimental" : false, "date" : "2026-03-17T21:02:03.8104715+00:00", "publisher" : "FHIR Infrastructure", "contact" : [{ "name" : "FHIR Infrastructure", "telecom" : [{ "system" : "url", "value" : "http://www.hl7.org/Special/committees/fiwg" }] }], "description" : "This cross-version ValueSet represents content from `http://hl7.org/fhir/ValueSet/v3-substanceAdminSubstitution|2015-07-31` for use in FHIR R5.", "jurisdiction" : [{ "coding" : [{ "system" : "http://unstats.un.org/unsd/methods/m49/m49.htm", "code" : "001", "display" : "World" }] }], "purpose" : "This value set is part of the cross-version definitions generated to enable use of the\r\nvalue set `http://hl7.org/fhir/ValueSet/v3-substanceAdminSubstitution|2015-07-31` as defined in FHIR DSTU2\r\nin FHIR R5.\r\n\r\nThe source value set is bound to the following FHIR DSTU2 elements:\r\n* \r\n\r\nNote that all concepts are included in this cross-version definition because no concepts have compatible representations\r\n\r\nFollowing are the generation technical comments:\r\n\nFHIR ValueSet `http://hl7.org/fhir/ValueSet/v3-substanceAdminSubstitution|2015-07-31`, defined in FHIR DSTU2 does not have any mapping to FHIR R5", "compose" : { "include" : [{ "system" : "http://hl7.org/fhir/v3/substanceAdminSubstitution", "version" : "1.0.2", "concept" : [{ "code" : "BC", "display" : "brand composition" }, { "code" : "E", "display" : "equivalent" }, { "code" : "EC", "display" : "equivalent composition" }, { "code" : "F", "display" : "formulary" }, { "code" : "G", "display" : "generic composition" }, { "code" : "N", "display" : "none" }, { "code" : "TB", "display" : "therapeutic brand" }, { "code" : "TE", "display" : "therapeutic alternative" }, { "code" : "TG", "display" : "therapeutic generic" }, { "code" : "_ActSubstanceAdminSubstitutionCode", "display" : "ActSubstanceAdminSubstitutionCode" }] }] }, "expansion" : { "timestamp" : "2026-03-17T21:02:03.8104715+00:00", "contains" : [{ "system" : "http://hl7.org/fhir/v3/substanceAdminSubstitution", "version" : "1.0.2", "code" : "BC", "display" : "brand composition" }, { "system" : "http://hl7.org/fhir/v3/substanceAdminSubstitution", "version" : "1.0.2", "code" : "E", "display" : "equivalent" }, { "system" : "http://hl7.org/fhir/v3/substanceAdminSubstitution", "version" : "1.0.2", "code" : "EC", "display" : "equivalent composition" }, { "system" : "http://hl7.org/fhir/v3/substanceAdminSubstitution", "version" : "1.0.2", "code" : "F", "display" : "formulary" }, { "system" : "http://hl7.org/fhir/v3/substanceAdminSubstitution", "version" : "1.0.2", "code" : "G", "display" : "generic composition" }, { "system" : "http://hl7.org/fhir/v3/substanceAdminSubstitution", "version" : "1.0.2", "code" : "N", "display" : "none" }, { "system" : "http://hl7.org/fhir/v3/substanceAdminSubstitution", "version" : "1.0.2", "code" : "TB", "display" : "therapeutic brand" }, { "system" : "http://hl7.org/fhir/v3/substanceAdminSubstitution", "version" : "1.0.2", "code" : "TE", "display" : "therapeutic alternative" }, { "system" : "http://hl7.org/fhir/v3/substanceAdminSubstitution", "version" : "1.0.2", "code" : "TG", "display" : "therapeutic generic" }, { "system" : "http://hl7.org/fhir/v3/substanceAdminSubstitution", "version" : "1.0.2", "code" : "_ActSubstanceAdminSubstitutionCode", "display" : "ActSubstanceAdminSubstitutionCode" }] } }